Zealand Pharma — Juli 2022
-
Det var tider - nu vil jeg hellere sidde i skyggen med en kold:)
-
det vil være magic og tak
-
lige over - nyd
-
Video til weekenden: Spændende Biotech-aktier: https://www.proinvestor.com/boards/104411/
-
Investtech teknisk analyse:
"Zealand Pharma har brudt den faldende trendkanal på mellemlang sigt, hvilket i første omgang indikerer svagere faldende takt. Aktien er brudt igennem et modstandsniveau og udløst købssignal fra langsigtet trading range. Aktien har støtte ved cirka 72.00 kroner og modstand ved cirka 194 kroner."
-
Marketscreener (ZEALAND-PHARMA):
-
Glimrende input - tak
-
Novo, Eli Lilly to dominate >$50B obesity market - Morgan Stanley
-
"The analysts highlight that biotechs such as Altimmune (ALT), Zealand Pharma (ZEAL) (OTCPK:ZLDPF), Hanmi, Regor Therapeutics, Sciwind Biosciences, and vTv Therapeutics (VTVT) are set to generate proof of concept data for their weight loss medications over the next 6–12 months."
-
En fantastisk god og varm dag på kontoret med Proinvestors biotek-darlings og Tour de France på skærmene.
Hansa Biopharma +40,95%
Bavarian Nordic + 5,94%
Zealand Pharma +2,97%
Genmab + 2,25% (nu -1,33% for 2022). -
Du går efter podieplads igen i år i Tour de Aktier:)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind